<DOC>
	<DOCNO>NCT02634723</DOCNO>
	<brief_summary>The purpose post-marketing safety study evaluate safety , immunogenicity , effectiveness ADVATE previously untreated patient ( PUPs ) China moderate severe hemophilia A .</brief_summary>
	<brief_title>Retrospective Chart Review Evaluate Safety Tolerability ADVATE Among Previously Untreated Patients China With Moderate Severe Hemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>1 . Previously untreated patient ( PUP ) China moderate severe hemophilia A . 2 . Investigator prescribe ADVATE predominant therapeutic agent management hemophilia A 3 . Informed consent form patient and/or legal representative need sign per local regulation 1 . Presence inherit acquire hemostatic defect hemophilia A , clinically significant chronic disease 2 . Participants participate another investigational FVIII drug study , participate clinical study involve investigational FVIII drug course observation period</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>